Publications by authors named "Itsuro Shimada"

Claim this Profile
D
Discovery of ASP6918, a KRAS G12C inhibitor: Synthesis and structure-activity relationships of 1-{2,7-diazaspiro[3.5]non-2-yl}prop-2-en-1-one derivatives as covalent inhibitors with good potency and oral activity for the treatment of solid tumors.
Tomoyoshi Imaizumi, Itsuro Shimada, Yoshiki Satake, Susumu Yamaki, Takanori Koike

Bioorg Med Chem· January 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Synthesis and structure-activity relationships of pyrazine-2-carboxamide derivatives as novel echinoderm microtubule-associated protein-like 4 (EML4)-anaplastic lymphoma kinase (ALK) inhibitors.
Kazuhiko Iikubo, Kazuo Kurosawa, Takahiro Matsuya, Yutaka Kondoh, Akio Kamikawa, Itsuro Shimada

Bioorg Med Chem· April 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of N-{2-Methoxy-4-[4-(4-methylpiperazin-1-yl)piperidin-1-yl]phenyl}-N'-[2-(propane-2-sulfonyl)phenyl]-1,3,5-triazine-2,4-diamine (ASP3026), a Potent and Selective Anaplastic Lymphoma Kinase (ALK) Inhibitor.
Kazuhiko Iikubo, Yutaka Kondoh, Itsuro Shimada, Takahiro Matsuya, Kenichi Mori

Chem Pharm Bull (Tokyo)· March 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Gilteritinib, a FLT3/AXL inhibitor, shows antileukemic activity in mouse models of FLT3 mutated acute myeloid leukemia.
Masamichi Mori, Naoki Kaneko, Yoko Ueno, Masaki Yamada, Ruriko Tanaka, Itsuro Shimada

Invest New Drugs· October 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Characterization and Thermodynamic Stability of Polymorphs of Di(arylamino) Aryl Compound ASP3026.
Kazuhiro Takeguchi, Yutaka Hirakura, Kouji Yamazaki, Itsuro Shimada, Shigeru Ieda

Chem Pharm Bull (Tokyo)· February 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The selective anaplastic lymphoma receptor tyrosine kinase inhibitor ASP3026 induces tumor regression and prolongs survival in non-small cell lung cancer model mice.
Masamichi Mori, Yoko Ueno, Satoshi Konagai, Hiroshi Fushiki, Itsuro Shimada

Mol Cancer Ther· February 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Atropisomeric 4-phenyl-4H-1,2,4-triazoles as selective glycine transporter 1 inhibitors.
Takashi Sugane, Takahiko Tobe, Wataru Hamaguchi, Itsuro Shimada, Kyoichi Maeno

J Med Chem· July 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Synthesis and biological evaluation of (4H-1,2,4-triazol-4-yl)isoquinoline derivatives as selective glycine transporter 1 inhibitors.
Takashi Sugane, Takahiko Tobe, Wataru Hamaguchi, Itsuro Shimada, Kyoichi Maeno

Bioorg Med Chem· January 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Synthesis and biological evaluation of 3-biphenyl-4-yl-4-phenyl-4H-1,2,4-triazoles as novel glycine transporter 1 inhibitors.
Takashi Sugane, Takahiko Tobe, Wataru Hamaguchi, Itsuro Shimada, Kyoichi Maeno, Yoshiaki Shimada

J Med Chem· January 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Synthesis and structure-activity relationships of a series of benzazepine derivatives as 5-HT2C receptor agonists.
Itsuro Shimada, Kyoichi Maeno, Yutaka Kondoh, Hidetaka Kaku, Keizo Sugasawa

Bioorg Med Chem· March 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Synthesis and structure-activity relationships of a series of substituted 2-(1H-furo[2,3-g]indazol-1-yl)ethylamine derivatives as 5-HT2C receptor agonists.
Itsuro Shimada, Kyoichi Maeno, Ken-ichi Kazuta, Hideki Kubota, Tetsuya Kimizuka

Bioorg Med Chem· February 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacological profile of YM348, a novel, potent and orally active 5-HT2C receptor agonist.
Yasuharu Kimura, Ken-ichi Hatanaka, Yuki Naitou, Kyoichi Maeno, Itsuro Shimada

Eur J Pharmacol· January 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis